FLT3 and acute lymphoblastic leukemia: Recent studies have increasingly demonstrated that FLT3 inhibitors exert a beneficial effect in a subset of patients; however, the specific nature of FLT3 mutations that may benefit pediatric ALL and AML patients remains to be determined [3,4,15,23,24].